Full-Time

Specialist

DP Manufacturing

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Mid

Norwood, MA, USA

This position is site-based, requiring full-time presence at Moderna’s site.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • BS in a relevant science or engineering discipline.
  • 2-3 years in biopharmaceutical operations, with substantial involvement in cGMP environments.
  • Training in cGMP practices and familiarity with electronic batch records and 21 CFR part 11 requirements is crucial.
  • Demonstrated ability to work independently with minimal supervision, excellent problem-solving skills, and effective communication and leadership in cross-functional settings.
Responsibilities
  • Adhere to and promote safe work practices, following safety procedures and guidelines.
  • Provide on-the-floor coaching and/or training for the manufacturing team in process execution, troubleshooting, cGMPs, and safety practices.
  • Lead tech transfers and serve as the manufacturing lead on various projects.
  • Lead and participate in cross-functional teams to drive changes, improvements, and resolve complex manufacturing operation issues.
  • Develop batch records, SOPs, and training materials in collaboration with process SMEs.
  • Partner closely with QA to ensure rapid disposition of batches, including timely reviews of batch records, protocols, and supporting deviation investigations.
  • Manage CAPA implementation and own the resolution process for manufacturing deviations.
  • Manage change controls and oversee the introduction of simple equipment/tools.
  • Prepare operations for new product introductions, technology transfers, and major capital projects.
  • Participate in equipment startup, commissioning, and validation activities.
  • Engage in forums for continuous improvement, gathering requirements, and prioritizing issues.
  • Support both internal and external audits to ensure regulatory compliance.
  • Maintain a flexible work schedule to meet production and project demands.
  • Escalate issues potentially impacting business objectives.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?